ClinicalTrials.gg
Drug

Cedazuridine clinical trials

studies test it
13
open now
8
in phase 3
2
first study started
2020

Counted the way a researcher would: Cedazuridine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses cedazuridine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the cedazuridine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
7 Jul 2020 · INQOVI · NDA 212576 (FDA, Drugs@FDA; in a combination)
European Union
15 Sept 2023 · Inaqovi · EMEA/H/C/005823 (EMA; in a combination)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cedazuridine
4

In one entry with another drug

Given together, or one or the other

Decitabine/cedazuridine
4
Oral decitabine/cedazuridine
2
Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
2

Studies by the year they started

13 studies that test it; most in 2023 (3)

Studies that test cedazuridine, by start year
YearStudies
20201
20212
20221
20233
20243
20263

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
7
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 5 · Other 8

Rutgers, The State University of New Jersey (2) · Taiho Oncology, Inc. (2) · Otsuka Australia Pharmaceutical Pty Ltd (1) · Astex Pharmaceuticals, Inc. (1) · PETHEMA Foundation (1) · National Cancer Institute (NCI) (1) · M.D. Anderson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1)

Often tested with

Tested in the same studies.

Decitabine (11) · Venetoclax (3) · Azacitidine (1) · Hydroxychloroquine (1) · Ivosidenib (1) · Olutasidenib (1) · Avapritinib (1) · Defactinib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 1 in phase 3

Studies that test cedazuridine, phase 3 first.

Studies

Open first, then newest update. How each study uses cedazuridine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 13

Given beside what is tested · 3 — cedazuridine is usual care or a partner of the new treatment

Codes

What other systems call cedazuridine · ClinicalTrials.gg INT001153

  • MeSH (NLM) C000633944cedazuridineOne source NLM
  • UNII (FDA) 39IS23Q1EWCEDAZURIDINEConfirmed FDA, NLM
  • RxNorm 2384449One source FDA
  • NCI Thesaurus C164146CedazuridineOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.